CytomX Therapeutics CTMX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.54M-75.9% | $76.2M-44.8% | $113.63M-10.3% | $141.1M+18.0% | $147.56M+23.8% | ||
| $69.1M-13.8% | $68.73M-17.6% | $62.28M-29.2% | $68.35M-17.7% | $80.2M+2.1% | ||
| $31.1M-1.0% | $29.84M+0.4% | $28.1M-12.0% | $29.63M-3.8% | $31.4M+5.4% | ||
| $100.2M-10.2% | $98.57M-12.9% | $90.39M-24.6% | $97.98M-13.9% | $111.6M+3.0% | ||
| -$64.66M-280% | -$22.37M-189% | $23.25M+246% | $43.13M+654% | $35.96M+232% | ||
| -181.9%-206pp | -29.4%-47.4pp | 20.5%+15.2pp | 30.6%+25.8pp | 24.4%+15.3pp | ||
| —— | —— | $14K— | $2K— | -$17K— | ||
| -$58.91M-241% | -$17.13M-153% | $28.26M+87.7% | $48.23M+220% | $41.84M+104% | ||
| $234K-0.8% | $237K+6.3% | $245K-80.1% | $248K-93.8% | $236K-94.0% | ||
| -$59.14M-242% | -$17.37M-154% | $28.02M— | $47.98M— | $41.6M— | ||
| -166.4%-195pp | -22.8%-45.9pp | 24.7%— | 34%— | 28.2%— | ||
| -$0.41-184% | -$0.04-110% | $0.41— | $0.57— | $0.49— | ||
| -$64.51M-279% | -$22.22M-188% | $23.39M+241% | $43.27M+637% | $36.11M+229% | ||
| -181.5%-206pp | -29.2%-47.4pp | 20.6%+15.2pp | 30.7%+25.8pp | 24.5%+15.3pp | ||
| -$64.66M-280% | -$22.37M-189% | $23.25M+246% | $43.13M+654% | $35.96M+232% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $35.5M in revenue over the trailing twelve months, down 75.9% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $59.1M over the trailing twelve months, a -166.4% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.41.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
